Implementation of Genotype-Guided Antiplatelet Therapy: Feasible but Not Without Obstacles
- PMID: 29615455
- PMCID: PMC5886747
- DOI: 10.1161/CIRCGEN.118.002118
Implementation of Genotype-Guided Antiplatelet Therapy: Feasible but Not Without Obstacles
Keywords: Editorials; aspirin; clopidogrel; genotype; percutaneous coronary intervention; pharmacogenetics.
Comment on
-
Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069. Circ Genom Precis Med. 2018. PMID: 29615454 Free PMC article.
References
-
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. - PubMed
-
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15. - PubMed
-
- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
